Please login to the form below

Not currently logged in
Email:
Password:

rheumatology

This page shows the latest rheumatology news and features for those working in and with pharma, biotech and healthcare.

Gilead and Galapagos JAK contender scores in RA trial

Gilead and Galapagos JAK contender scores in RA trial

The FINCH 2 trial of filgotinib in adults with moderately-to-severely active rheumatoid arthritis achieved its primary endpoint in the proportion of patients achieving an American College of Rheumatology 20%

Latest news

More from news
Approximately 1 fully matching, plus 80 partially matching documents found.

Latest Intelligence

  • Opening up innovation Opening up innovation

    We are trying to build a holistic portfolio. The first wave will be rheumatology. ... Prior to GSK, which he joined to lead the immuno-inflammation therapy unit, Paul-Peter worked in academia as a professor of medicine, in particular clinical immunology

  • Case study: Immunology education Case study: Immunology education

    Challenge. There are immunological links between immune-mediated inflammatory diseases (IMIDs) in dermatology, gastroenterology and rheumatology, with patients often presenting with multiple conditions. ... Setting up a virtual biologics clinic

  • Case study: Immunology education Case study: Immunology education

    Challenge. There are immunological links between immune-mediated inflammatory diseases (IMIDs) in dermatology, gastroenterology and rheumatology, with patients often presenting with multiple conditions. ... Setting up a virtual biologics clinic

  • Pharma deals during April 2014 Pharma deals during April 2014

    associated with nephrotic syndrome, certain rheumatology-related conditions, and infantile spasms.

  • Pharma deals during February 2014 Pharma deals during February 2014

    Questor and Retrophin are is now in litigation over two synthetic versions of Acthar (ACTH), a corticotropin with 19 indications, many in rare diseases including infantile spasms, MS, nephrology, and rheumatology.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

  • Bringing the NHS into the 21st century

    We have consultants specialising in cardiology, endocrine, ENT, gynaecology, haematology, neurology, respiratory, orthopaedics, rheumatology, and urology.

  • Event: EULAR Annual European Congress of Rheumatology 2016

    Event: EULAR Annual European Congress of Rheumatology 2016. We are delighted to be attending the EULAR Annual European Congress of Rheumatology in June.

  • EULAR Annual European Congress of Rheumatology 2017

    EULAR Annual European Congress of Rheumatology 2017. Join us at EULAR Congress 2017 in Madrid, 14-17 June. ... We are delighted to be attending and presenting at this year’ s EULAR Annual European Congress of Rheumatology in June.

  • The Biosimilar Challenge

    In fact, recent self-funded work, showed that 89% of UK payers now positively endorse the use of biosimilars across a range of therapy areas – especially in rheumatology. ... The pressure is now on to undertake the same in rheumatology, dermatology and

  • Biosimilars: Getting the flock to market

    Medical authorities including the British Gastroenterology Society and the British Society for Rheumatology have accepted the evidence that biosimilars perform as well as the originator drugs, and NICE now recommends the

More from PMHub
Approximately 2 fully matching, plus 18 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics